Opna Bio
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Route De La Corniche 6, Epalinges, Vaud,...Website
www.opnabio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Opna Bio
Based out of Lausanne, Opna Bio, is a biopharmaceutical company with a focus on oncology therapeutics.Explore more
Opna Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Opna Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Opna Bio has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Opna Bio has new funding data
Website visits: Recent activity has been detected on your website
Opna Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Opna Bio
Product Launch: Get notified when Opna Bio launches new products
Check out if Opna Bio is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Opna Bio recently announced quarterly report
Click to see if Opna Bio had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Opna Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Opna Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Opna Bio.
Opna Bio financials insights
Gather financial insights about Opna Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$38M
Opna Bio Tech Stack
A closer look at the technologies used by Opna Bio
See more technologies
Opna Bio News & Media
Opna Bio Announces Interim Data from Phase 1 Combination Study of OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis
SAN DIEGO--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced interim data from its lead clinical program, OPN-2853, in patients with advanced myelofibrosis showing encouraging levels of spleen reduction, with minimal toxicities and adverse events. Preclinical data from a second program, OPN-6602, showed significant tumor regression in multiple myeloma models as a single agent and in combinatioOpna Bio Announces 2024 ASH Presentations Highlighting Interim Data from Phase 1 Combo Study of BET Inhibitor OPN-2853 with Ruxolitinib in Myelofibrosis, and Promising Preclinical Data with EP300/CBP Bromodomain Inhibitor OPN-6602 in Multiple Myeloma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that two abstracts have been accepted for poster presentations at the American Society of Hematology (ASH) annual meeting, taking place Dec 7-10, 2024 in San Diego. The presentations will highlight data from Opna’s lead clinical programs, OPN-2853 and OPN-6602. The data presentations will include an interim anOpna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Opna Bio announced that it has dosed the first patient with OPN-6602, a potent and selective EP300/CBP bromodomain inhibitor, in a Phase 1 clinical study in multiple myeloma. The trial is expected to enroll up to 130 total patients with relapsed or refractory multiple myeloma at sites in the U.S. Multiple myeloma is a type of blood cancer derived from malignant plasma cells in the bone marrow. There are approximately 180,000Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer therapeutics, presented promising preclinical data in two programs, OPN-6602, a dual EP300/CBP inhibitor in multiple myeloma, and OPN-9840, an oral, non-covalent TEAD inhibitor in malignant mesothelioma and metastatic melanoma. Data were shared at the American Association of Cancer Research (AACR) Annual Meeting, taking place April 5-10, 2024 in San Diego. OP
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Opna Bio
Sign Up For FreeTo access detailed company insights
Based out of Lausanne, Opna Bio, is a biopharmaceutical company with a focus on oncology therapeutics.... Read More
